Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $4.3 Million Registered Direct Offering [Yahoo! Finance]
Lixte Biotechnology Holdings, Inc. (LIXT)
NASDAQ:AMEX Investor Relations:
lixte.com/investor_information_02.php
Company Research
Source: Yahoo! Finance
placement agent in a $4.3 million registered direct offering for Lixte Biotechnology Holdings, Inc . (NASDAQ: LIXT). Lixte Biotechnology Holdings, Inc., a clinical stage pharmaceutical company focused on advancing cancer treatments, entered into definitive agreements with accredited investors for the purchase and sale of shares of Common Stock and pre funded and investor warrants. The entire transaction has been priced at the market under Nasdaq rules. The offering consisted of 1,051,342 Common Units or Pre Funded Units. Each Common Unit included one share of Common Stock and one Common Warrant to purchase one share of Common Stock at an exercise price of $3.96. Each Pre Funded Unit included one Pre Funded Warrant with an exercise price of $0.00001 and one Common Warrant. The public offering price per Common Unit was $4.09 and $4.08999 per Pre Funded Unit. The Common Warrants are immediately exercisable and expire sixty months from issuance. Aggregate gross proceeds to the Compa
Show less
Read more
Impact Snapshot
Event Time:
LIXT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LIXT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LIXT alerts
High impacting Lixte Biotechnology Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
LIXT
News
- Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $4.3 Million Registered Direct OfferingGlobeNewswire
- Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq RulesGlobeNewswire
- LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer TreatmentGlobeNewswire
- LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3GlobeNewswire
- LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition PlansGlobeNewswire
LIXT
Sec Filings
- 12/22/25 - Form 8-K
- 12/19/25 - Form 424B5
- 12/11/25 - Form 8-K
- LIXT's page on the SEC website